RecruitingPhase 2NCT03025477

Two Therapeutic Strategies in First-line in Patients With Epithelial Advanced Ovarian Cancer

Randomized Study Assessing Two Strategies of First Line: a Strategy With Intraperitoneal Chemotherapy and a Strategy With Total Intravenous Strategy, in Patients With Epithelial Advanced Ovarian Cancer


Sponsor

Groupe Hospitalier Diaconesses Croix Saint-Simon

Enrollment

84 participants

Start Date

Oct 1, 2016

Study Type

INTERVENTIONAL

Conditions

Summary

CHIMOVIP is a study to determine the best therapeutic strategy in patient with ovarian advanced cancer.


Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This trial compares two different treatment strategies for women with advanced ovarian cancer (stage III or IV) to find out which approach leads to better outcomes after surgery. **You may be eligible if...** - You are between 18 and 74 years old - You have been diagnosed with advanced ovarian, fallopian tube, or primary peritoneal cancer (stage III or IV) confirmed by a tissue biopsy - You have recently had surgery (within 3 weeks) to remove as much of the cancer as possible, or are about to start chemotherapy before surgery - Your blood counts and kidney function are within acceptable ranges **You may NOT be eligible if...** - Your cancer has spread outside the abdomen to distant organs (except lymph nodes or the lining of the lungs) - You have received chemotherapy for ovarian cancer previously - Your heart's pumping function (ejection fraction) is below 50% - You have had another invasive cancer within the past 5 years - You are pregnant or breastfeeding - You have known allergies to the study drugs Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGCC0 - Carboplatin (IV) - Paclitaxel (IV)

(6 cycles)

DRUGCC0 - Cisplatin (IP) - Epirubicin (IV)

(6 cycles)

DRUGCC>0 - Carboplatin (IV)- Paclitaxel (IV)

* carboplatin (IV) - paclitaxel (IV) (3 cycles) * Interval surgery * Carboplatin (IV) - paclitaxel (IV) (3 cycles)

DRUGCC>0 - Cisplatin (IP/IV)- Epirubicin (IV)

* Cisplatin (IV) - Epirubicin (IV) (3 cycles) * Interval surgery : * if CC0: Cisplatin (IP) - Epirubicin (IV) (3 cycles) * if CC\>0 Cisplatin (IV)- Epirubicin (IV) (3 cycles)


Locations(7)

Centre Georges François Leclerc

Dijon, France

Institut Hospitalier Franco-Britannique

Levallois-Perret, France

Groupe Hospitalier Diaconesses Croix Saint Simon

Paris, France

Hôpital Saint Antoine

Paris, France

Hôpital Poissy Saint Germain

Poissy, France

CHU Poitiers

Poitiers, France

Centre Hospitalier Senlis

Senlis, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03025477


Related Trials